Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Oral Colon Delivery Of Insulin With The Aid Of Functional Adjuvants.

A. Maroni, L. Zema, M. D. Del Curto, A. Foppoli, A. Gazzaniga
Published 2012 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Oral colon delivery is currently considered of importance not only for the treatment of local pathologies, such as primarily inflammatory bowel disease (IBD), but also as a means of accomplishing systemic therapeutic goals. Although the large bowel fails to be ideally suited for absorption processes, it may indeed offer a number of advantages over the small intestine, including a long transit time, lower levels of peptidases and higher responsiveness to permeation enhancers. Accordingly, it has been under extensive investigation as a possible strategy to improve the oral bioavailability of peptide and protein drugs. Because of a strong underlying rationale, most of these studies have focused on insulin. In the present review, the impact of key anatomical and physiological characteristics of the colon on its viability as a protein release site is discussed. Moreover, the main formulation approaches to oral colon targeting are outlined along with the design features and performance of insulin-based devices.
This paper references
10.1002/BDD.2510110602
Microbially controlled drug delivery to the colon
A. Rubinstein (1990)
10.1023/A:1016008419367
Oral Controlled Release Technology for Peptides: Status and Future Prospects
J. Fix (2004)
10.1021/JS980125Q
Enhanced colonic and rectal absorption of insulin using a multiple emulsion containing eicosapentaenoic acid and docosahexaenoic acid.
A. Suzuki (1998)
10.1152/AJPGI.1997.273.2.G553
Survival of human pancreatic enzymes during small bowel transit: effect of nutrients, bile acids, and enzymes.
G. Holtmann (1997)
10.1016/J.JCONREL.2004.02.023
Pharmaceutical design of a novel colon-targeted delivery system using two-layer-coated tablets of three different pharmaceutical formulations, supported by clinical evidence in humans.
T. Goto (2004)
10.3109/10611869808997884
Eudragit E as coating material for the pH-controlled drug release in the topical treatment of inflammatory bowel disease (IBD).
C. Leopold (1998)
10.1016/j.ijpharm.2010.04.044
The transit of dosage forms through the colon.
C. Wilson (2010)
10.1016/0168-3659(95)00059-H
Nanoparticles as carriers for oral peptide absorption: Studies on particle uptake and fate
A. T. Florence (1995)
10.1016/S0168-3659(97)00204-6
The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins.
A. Bernkop-Schnürch (1998)
10.1016/0169-409X(89)90018-5
Penetration and enzymatic barriers to peptide and protein absorption
V. Lee (1989)
10.1081/DDC-120003452
Effect of Bioadhesive Polymers, Sodium Salicylate, Polyoxyethylene-9-lauryl Ether, and Method of Preparation on the Relative Hypoglycemia Produced by Insulin Enteric-Coated Capsules in Diabetic Beagle Dogs
E. Hosny (2002)
10.1002/JPS.2600831020
Enhancement of intestinal insulin absorption by bile salt-fatty acid mixed micelles in dogs.
J. C. Scott-Moncrieff (1994)
10.1080/10611860500206583
In vitro and in vivo evaluation of pectin beads for the colon delivery of β-lactamases
S. Bourgeois (2005)
10.1016/S0378-5173(98)00082-9
Design and evaluation of a new capsule-type dosage form for colon-targeted delivery of drugs
T. Ishibashi (1998)
10.1002/(SICI)1097-0029(20000515)49:4<346::AID-JEMT3>3.0.CO;2-B
Intestinal absorption of peptides through the enterocytes
E. Ziv (2000)
10.1615/CRITREVTHERDRUGCARRIERSYST.V23.I2.20
Approaches to oral drug delivery for challenging molecules.
G. Mustata (2006)
10.1016/J.ADDR.2004.08.007
Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease.
U. Klotz (2005)
10.1023/B:PHAM.0000016244.88820.28
In Situ Ileal Absorption of Insulin in Rats: Effects of Hyaluronidase Pretreatment Diminishing the Mucous/Glycocalyx Layers
M. Morishita (2004)
10.1111/j.2042-7158.1994.tb03880.x
Subcellular Distribution of Proteolytic Activities Degrading Bioactive Peptides and Analogues in the Rat Small Intestinal and Colonic Enterocytes
J. M. Bai (1994)
Microemulsions for improved peptide absorption from the gastrointestinal tract.
W. Ritschel (1991)
10.1248/BPB.17.327
Drug absorption from large intestine: physicochemical factors governing drug absorption.
T. Kimura (1994)
Colonic drug delivery of small peptides
S. Rao (1995)
10.1016/J.IJPHARM.2006.07.045
Time and pH dependent colon specific, pulsatile delivery of theophylline for nocturnal asthma.
V. Mastiholimath (2007)
10.2741/KARAM
Lineage commitment and maturation of epithelial cells in the gut.
S. Karam (1999)
10.1111/j.1365-2036.2005.02683.x
Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging
C. Schiller (2005)
10.1111/j.2042-7158.1995.tb05858.x
The Involvement of Cytosolic Chymotrypsin‐like, Trypsin‐like, and Cucumsin‐like Activities in Degradation of Insulin and Insulin‐like Growth Factor I by Epithelial Tissues
J. M. Bai (1995)
10.1136/gut.48.4.571
Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs
S. Nugent (2001)
10.1016/S0168-3659(99)00006-1
Modulating insulin-release profile from pH/thermosensitive polymeric beads through polymer molecular weight.
C. Ramkissoon-Ganorkar (1999)
10.1016/S0378-5173(00)00454-3
Preparation of enteric coated timed-release press-coated tablets and evaluation of their function by in vitro and in vivo tests for colon targeting.
E. Fukui (2000)
10.1248/BPB.18.929
Metabolism of peptide drugs by the microorganisms in rat cecal contents.
H. Tozaki (1995)
10.1248/BPB.16.68
Site-dependent effect of aprotinin, sodium caprate, Na2EDTA and sodium glycocholate on intestinal absorption of insulin.
M. Morishita (1993)
10.1016/S0169-409X(97)00076-8
Peptide drug delivery: Colonic and rectal absorption
M. Mackay (1997)
Delivery systems for biopharmaceuticals.
S. Davis (1992)
10.1016/S1557-0843(06)80019-9
Advances in insulin delivery systems and devices: Beyond the vial and syringe
T. Flood (2006)
10.1016/S1359-6446(01)01962-6
Insulin therapies - past, present and future.
O. Pillai (2001)
10.1016/S1557-0843(06)80010-2
The role of basal insulin therapy in patients with type 2 diabetes mellitus
V. Fonseca (2006)
10.1016/S0378-5173(97)00347-5
In vivo performance of time-controlled explosion system (TES) in GI physiology regulated dogs
S. Murata (1998)
Development of a colonic release capsule dosage form and the absorption of insulin.
M. Kraeling (1992)
10.1016/S0168-3659(97)01634-9
A new multiparticulate delayed release system.: Part I: Dissolution properties and release mechanism
P. Schultz (1997)
10.2165/00137696-200503030-00003
Polymer colon drug delivery systems and their application to peptides, proteins, and nucleic acids
S. Bourgeois (2005)
10.1080/10611860290022697
Studies on the Development of Colon-targeted Delivery Systems for Celecoxib in the Prevention of Colorectal Cancer
Y. Krishnaiah (2002)
10.1615/CRITREVTHERDRUGCARRIERSYST.V19.I6.10
The colon as a possible target for orally administered peptide and protein drugs.
S. Haupt (2002)
10.1016/0378-5173(93)90344-F
An in vivo investigation into the suitability of pH dependent polymers for colonic targeting
M. Ashford (1993)
10.1016/S0169-409X(00)00137-X
Delivery systems for penetration enhancement of peptide and protein drugs: design considerations.
U. B. Kompella (2001)
10.1016/J.EJPS.2004.05.002
Different HPMC viscosity grades as coating agents for an oral time and/or site-controlled delivery system: a study on process parameters and in vitro performances.
M. E. Sangalli (2004)
10.1016/S0168-3659(96)01586-6
The challenge of proteolytic enzymes in intestinal peptide delivery
P. Langguth (1997)
10.3109/03639049209040854
Influence of extrusion-spheronization processing on the physical properties of d-Indobufen pellets containing pH adjusters
R. Bianchini (1992)
10.1126/SCIENCE.3526553
A new approach to the oral administration of insulin and other peptide drugs.
M. Saffran (1986)
10.1002/JPS.2600820902
Gastrointestinal parameters that influence oral medications.
J. Dressman (1993)
10.1211/0022357001777315
Colon Delivery Efficiencies of Intestinal Pressure‐controlled Colon Delivery Capsules Prepared by a Coating Machine in Human Subjects
Z. Hu (2000)
10.1089/1520915041705929
The physiological rationale for oral insulin administration.
E. Arbit (2004)
Colon-specific delivery of peptide drugs and anti-inflammatory drugs using chitosan capsules
A. Yamamoto (2000)
10.1677/JOE.0.1640001
Orally administered, insulin-loaded amidated pectin hydrogel beads sustain plasma concentrations of insulin in streptozotocin-diabetic rats.
C. Musabayane (2000)
10.1016/S1461-5347(98)00100-X
Macromolecules as safe penetration enhancers for hydrophilic drugs—a fiction?
H. Junginger (1998)
10.1016/J.JCONREL.2003.12.022
Oral insulin delivery using P(MAA-g-EG) hydrogels: effects of network morphology on insulin delivery characteristics.
K. Nakamura (2004)
10.1002/1520-6017(200101)90:1<89::AID-JPS10>3.0.CO;2-A
Enhanced absorption of insulin and (Asu(1,7))eel-calcitonin using novel azopolymer-coated pellets for colon-specific drug delivery.
H. Tozaki (2001)
Ibuprofen delayed release dosage forms : a proposal for the preparation of an in vitro/in vivo pulsatile system
U. Conte (1992)
10.1021/JS950180O
An organic acid-induced sigmoidal release system for oral controlled-release preparations. 2. Permeability enhancement of Eudragit RS coating led by the physicochemical interactions with organic acid.
S. Narisawa (1996)
10.1016/0169-409X(92)90016-J
C) Means to enhance penetration
W. Shen (1992)
10.1615/CRITREVTHERDRUGCARRIERSYST.V24.I1.30
Oral colon-specific drug delivery of protein and peptide drugs.
V. Sinha (2007)
10.1016/0378-5173(93)90404-4
Degradation of proteins by guinea pig intestinal enzymes
K. Ikesue (1993)
10.1016/S0168-3659(99)00005-X
Evaluation of colonic absorbability of drugs in dogs using a novel colon-targeted delivery capsule (CTDC).
T. Ishibashi (1999)
10.1248/CPB.40.3036
Design and preparation of pulsatile release tablet as a new oral drug delivery system.
R. Ishino (1992)
10.1021/JS970018G
Chitosan Capsules for Colon-Specific Drug Delivery: Improvement of Insulin Absorption from the Rat Colon
H. Tozaki (1997)
10.1615/CRITREVTHERDRUGCARRIERSYST.V19.I2.20
Oral delivery of proteins: progress and prognostication.
R. Shah (2002)
10.1016/j.ejpb.2008.12.002
Feasibility, stability and release performance of a time-dependent insulin delivery system intended for oral colon release.
A. Maroni (2009)
10.1016/0168-3659(96)01352-1
Structural requirements for intestinal absorption of peptide drugs
G. Pauletti (1996)
10.1016/S0168-3659(01)00291-7
In vitro and in vivo evaluation of an oral system for time and/or site-specific drug delivery.
M. E. Sangalli (2001)
10.1023/A:1022660305931
Effect of Colonic Lactulose Availability on the Timing of Drug Release Onset in Vivo from a Unique Colon-Specific Drug Delivery System (CODES™)
L. Yang (2004)
10.1002/JPS.20802
Different HPMC viscosity grades as coating agents for an oral time and/or site-controlled delivery system: an investigation into the mechanisms governing drug release.
L. Zema (2007)
10.1023/A:1018990928259
Differential Effects of Anionic, Cationic, Nonionic, and Physiologic Surfactants on the Dissociation, α-Chymotryptic Degradation, and Enteral Absorption of Insulin Hexamers
Z. Shao (2004)
10.1016/S0928-0987(03)00139-8
In vivo pharmacokinetics in human volunteers: oral administered guar gum-based colon-targeted 5-fluorouracil tablets.
Y. Krishnaiah (2003)
10.1016/S0168-3659(96)01578-7
Insulin and the gastrointestinal tract
M. Saffran (1997)
10.1016/S0169-409X(96)00432-2
In vitro permeability of peptidomimetic drugs : the role of polarized efflux pathways as additional barriers to absorption
P. S. Burton (1997)
10.1211/0022357022052
Potential utility of various protease inhibitors for improving the intestinal absorption of insulin in rats
H. Liu (2003)
10.1136/gut.29.8.1035
Measurement of gastrointestinal pH profiles in normal ambulant human subjects.
D. F. Evans (1988)
10.1023/A:1018910114436
An Organic Acid-Induced Sigmoidal Release System for Oral Controlled-Release Preparations
S. Narisawa (2004)
10.1016/S0169-409X(97)00071-9
Physiology of the colorectal barrier
C. Edwards (1997)
10.1517/17425247.2.5.855
Oral pulsatile drug delivery systems
A. Maroni (2005)
10.1016/J.JCONREL.2005.10.029
Novel oral insulin delivery systems based on complexation polymer hydrogels: single and multiple administration studies in type 1 and 2 diabetic rats.
M. Morishita (2006)
10.3109/03639049009074381
Effects of Gastrointestinal Administration of Human Insulin and a Human Insulin-Deae-Dextran Complex Entrapped in Different Compound Liposomes on Blood Glucose in Rats
A. Manosroi (1990)
10.1055/s-0031-1296163
In vitro and in vivo evaluation of insulin microspheres containing protease inhibitor.
M. Jelvehgari (2011)
10.1081/DDC-100102305
Basic Coating Polymers for the Colon-Specific Drug Delivery in Inflammatory Bowel Disease
C. Leopold (2000)
10.1248/CPB.43.311
Evaluation of hydroxyethylcellulose as a hydrophilic swellable material for delayed-release tablets
M. Matsuo (1995)
10.1677/JOE.0.1310267
Oral insulin in diabetic dogs.
M. Saffran (1991)
Oral absorption of peptides and proteins
C. TenHoor (1992)
10.1016/0378-5173(94)90406-5
Enteric coated timed release systems for colonic targeting
I. Wilding (1994)
10.1002/jps.22560
Oral delivery system for two-pulse colonic release of protein drugs and protease inhibitor/absorption enhancer compounds.
M. D. Del Curto (2011)
10.1615/CRITREVTHERDRUGCARRIERSYST.V12.I4.30
Targeting of peptide and protein drugs to specific sites in the oral route.
J. M. Bai (1995)
10.1016/J.JCONREL.2004.03.008
Mucosal insulin delivery systems based on complexation polymer hydrogels: effect of particle size on insulin enteral absorption.
M. Morishita (2004)
10.1208/pt060116
Eudragit S100 entrapped insulin microspheres for oral delivery
D. Jain (2008)
10.3109/10717549709051893
Evaluation of a Gastro-Resistant Pulsed Release Delivery System (Pulsincap) in Humans
C. Wilson (1997)
10.3109/03639049309069340
High-viscosity HPMC as a film-coating agent
G. Maffione (1993)
In vitro and in vivo analysis of colon specificity of calcium pectinate formulations
A. Rubinstein (1995)
10.1016/S1262-3636(06)72804-X
Alternatives routes of insulin delivery.
V. Lassmann-Vague (2006)
Drug delivery systems for challenging molecules
S. S. Davis (1998)
10.1128/AEM.55.3.679-683.1989
Significance of microflora in proteolysis in the colon.
S. A. Gibson (1989)
Identification of insulin receptors in epithelial cells from duodenum, jejunum, ileum, caecum, colon and rectum in the rat.
M. Fernández-Moreno (1987)
10.1615/CRITREVTHERDRUGCARRIERSYST.V25.I3.10
Mucoadhesion and the gastrointestinal tract.
F. J. O. Varum (2008)
Time-dependent oral delivery systems for colon targeting
A. Gazzaniga (1995)
10.1016/S0169-409X(98)00075-1
Oral insulin delivery.
Carino (1999)
10.1016/S0011-393X(97)80073-2
Intracecally administered insulin in chronically diabetic pigs
A. Elias (1997)
10.1023/A:1015887001987
Chemical Stability of Insulin. 2. Formation of Higher Molecular Weight Transformation Products During Storage of Pharmaceutical Preparations
J. Brange (2004)
10.1016/0306-3623(92)90047-N
Effective portal insulin delivery with enzyme-protected capsules in pancreatectomized pigs.
A. Elias (1992)
10.1080/10601320601030707
Insulin Release Behavior of Poly(methacrylamide‐co‐N‐vinyl‐2‐pyrrolidone‐co‐itaconic acid) Hydrogel: An Interesting Probe. Part II
S. Bajpai (2007)
10.1111/j.1463-1326.2009.01150.x
Oral insulin – a review of current status
H. Iyer (2010)
Microencapsulated lipid cores for site-specific delivery of corticosteroid and peptide drugs to the colonic region
D. Torres (2003)
10.3109/03639049309069339
d-Indobufen Extended-Release Pellets Prepared by Coating with Aqueous Polymer Dispersions
R. Bianchini (1993)
10.1016/J.JCONREL.2005.05.017
Nitric oxide donors can enhance the intestinal transport and absorption of insulin and [Asu(1,7)]-eel calcitonin in rats.
G. Fetih (2005)
Mucosal penetration enhancers for facilitation of peptide and protein drug absorption.
V. Lee (1991)
10.1016/0169-409X(92)90005-B
(D) Routes of delivery: Case studies
P. Smith (1992)
10.1002/JPS.21183
Past, present, and future technologies for oral delivery of therapeutic proteins.
R. Singh (2008)
10.1016/0378-5173(94)00386-J
Using microemulsion formulations for oral drug delivery of therapeutic peptides
J. M. Sarciaux (1995)
10.1002/(SICI)1520-6017(200004)89:4<429::AID-JPS1>3.0.CO;2-J
Intestinal permeation enhancers.
B. Aungst (2000)
10.1016/J.IJPHARM.2005.09.028
Effects of absorption promoters on insulin absorption through colon-targeted delivery.
M. Katsuma (2006)
10.1517/17425247.5.1.45
Nanoparticle strategies for the oral delivery of insulin
C. Damgé (2008)
Colonic delivery of peptide and protein drugs : consideration of intracellular proteolytic enzymes
J. P. Bai (1995)
10.1016/0142-9612(91)90056-G
Hydrogels for site-specific oral drug delivery: synthesis and characterization.
H. Brøndsted (1991)
10.3109/03639049509069248
Effective Intestinal Absorption of Insulin in Diabetic Rats Using Enteric Coated Capsules Containing Sodium Salicylate
E. A. Hoeny (1995)
10.1016/0169-409X(91)90050-M
Cell biology and active transport processes in the colon
J. Hastewell (1991)
10.1016/J.IJPHARM.2003.07.008
Formulation parameters affecting the performance of coated gelatin capsules with pulsatile release profiles.
T. Bussemer (2003)
10.1002/JPS.2600841107
Effects of polyacrylic polymers on the lumenal proteolysis of peptide drugs in the colon.
J. M. Bai (1995)
10.1016/J.DRUDIS.2006.08.005
Is the oral route possible for peptide and protein drug delivery?
M. Morishita (2006)
Oral colon-specific drug delivery: Design strategies
A. Gazzaniga (1994)
10.1021/JS980337N
Oral delivery of insulin using pH-responsive complexation gels.
A. Lowman (1999)
10.1081/DDC-120030930
Insulin‐Loaded Calcium Pectinate Nanoparticles: Effects of Pectin Molecular Weight and Formulation pH
K. Cheng (2004)
10.1016/0378-5173(86)90069-4
Targeted enteral delivery of insulin to rats
E. Touitou (1986)
10.1016/S0140-6736(06)68341-4
Type 1 diabetes
D. Daneman (2006)
10.1016/J.IJPHARM.2003.09.036
Colonic drug delivery of 5-fluorouracil: an in vitro evaluation.
V. Sinha (2004)
10.1016/0168-3659(95)00145-X
Transmembrane transport of peptide type compounds: prospects for oral delivery.
E. Lipka (1996)
10.2165/00063030-200519030-00003
Oral Delivery of Peptide Drugs
J. Hamman (2012)
10.3109/10611860903302815
Design of oral insulin delivery systems
T. Wong (2010)
10.1016/J.IJPHARM.2005.01.022
Current strategies used to enhance the paracellular transport of therapeutic polypeptides across the intestinal epithelium.
Nazila Salamat-Miller (2005)
10.1007/s001250050081
Biochemical and morpho-cytochemical evidence for the intestinal absorption of insulin in control and diabetic rats. Comparison between the effectiveness of duodenal and colon mucosa
M. Bendayan (2009)
10.1016/S0168-3659(97)00201-0
Evaluation of intestinal pressure-controlled colon delivery capsule containing caffeine as a model drug in human volunteers.
M. Muraoka (1998)
10.1002/JPS.20848
Peptide drug delivery strategies for the treatment of diabetes.
N. Sadrzadeh (2007)
10.1016/J.ADDR.2007.08.019
Current challenges in non-invasive insulin delivery systems: a comparative review.
E. Khafagy (2007)
10.1016/0168-3659(96)01353-3
Enhancement of the intestinal absorption of peptides and nonpeptides
B. Aungst (1996)
10.3109/10611869409015891
Development of a novel drug release system, time-controlled explosion system (TES). I. Concept and design.
S. Ueda (1994)
Oral chronotopic® drug delivery systems: Achievement of time and/or site specificity
A. Gazzaniga (1994)
10.1021/JS9704588
Scintigraphic evaluation of a new capsule-type colon specific drug delivery system in healthy volunteers.
T. Ishibashi (1998)
10.1016/0168-3659(95)00114-X
The tolerability of multiple oral doses of Pulsincap™ capsules in healthy volunteers
J. Binns (1996)
10.1021/JS960297S
Toward understanding insulin fibrillation.
J. Brange (1997)
10.1016/0169-409X(95)00129-U
The intestinal peptide carrier: A potential transport system for small peptide derived drugs
E. Walter (1996)
10.1111/J.2042-7158.1996.TB00633.X
Intestinal Absorption of Insulin in the Absence of Intestinal-fluid Enzymes
H. Tozaki (1996)
10.1002/JBM.B.30279
Using pH-sensitive hydrogels containing cubane as a crosslinking agent for oral delivery of insulin.
M. Mahkam (2005)
10.1016/0168-3659(94)90072-8
Mechanisms of absorption enhancement and tight junction regulation
J. Hochman (1994)
10.1023/A:1018968611962
Effects of Various Protease Inhibitors on the Intestinal Absorption and Degradation of Insulin in Rats
A. Yamamoto (2004)
10.1016/J.EJPS.2006.06.004
Site of drug absorption after oral administration: assessment of membrane permeability and luminal concentration of drugs in each segment of gastrointestinal tract.
Y. Masaoka (2006)
10.1136/gut.31.11.1318
Pancreatic secretory trypsin inhibitor in gastrointestinal mucosa and gastric juice.
T. C. Freeman (1990)
10.1023/A:1015893832222
Degradation of Insulin by Trypsin and Alpha-Chymotrypsin
R. J. Schilling (2004)
10.1016/J.JCONREL.2003.10.023
Development of pulsatile release tablets with swelling and rupturable layers.
S. Sungthongjeen (2004)
10.1016/S0168-3659(98)00106-0
In vivo drug release behavior in dogs from a new colon-targeted delivery system.
T. Ishibashi (1999)
10.1016/0168-3659(94)90071-X
Overcoming enzymatic and absorption barriers to non-parenterally administered protein and peptide drugs
X. Zhou (1994)
10.1002/jps.21761
Preparation and evaluation of an oral delivery system for time-dependent colon release of insulin and selected protease inhibitor and absorption enhancer compounds.
M. D. Del Curto (2009)
10.1517/17425247.1.1.141
Particle uptake by Peyer’s patches: a pathway for drug and vaccine delivery
Monjed Shakweh (2004)
10.1517/17425247.3.5.583
Time-controlled oral delivery systems for colon targeting
A. Gazzaniga (2006)
Development of an azopolymer based colonic release capsule for delivering proteins/macromolecules.
C. L. Cheng (1994)
10.1023/A:1012159818727
The Effect of Intestinal Bacteria Adherence on Drug Diffusion Through Solid Films Under Stationary Conditions
A. Rubinstein (2004)
10.1007/s11095-005-6137-z
Region-Dependent Role of the Mucous/Glycocalyx Layers in Insulin Permeation Across Rat Small Intestinal Membrane
Y. Aoki (2005)
10.1016/J.IJPHARM.2005.03.004
Role of the mucous/glycocalyx layers in insulin permeation across the rat ileal membrane.
Y. Aoki (2005)
10.1016/0024-3205(82)90673-7
The absorption of insulin from various regions of the rat intestine.
M. Kidron (1982)
10.1016/S1773-2247(10)50072-8
Mechanisms of antibiotic resistance and delivery strategies to prevent its emergence
M. Khoder (2010)
10.1016/0169-409X(91)90051-D
Colon-specific drug delivery
D. Friend (1991)
10.1016/S0378-5173(98)00210-5
Improving insulin enteral absorption using water-in-oil-in-water emulsion
M. Morishita (1998)
10.1007/s11095-005-9175-7
Novel Mucosal Insulin Delivery Systems Based on Fusogenic Liposomes
T. Goto (2005)
10.1038/nrd836
New horizons — alternative routes for insulin therapy
D. Owens (2002)
10.1016/0306-3623(91)90440-H
Insulin and C-peptide levels following oral administration of insulin in intestinal-enzyme protected capsules.
G. Gwinup (1991)
10.1615/CRITREVTHERDRUGCARRIERSYST.V18.I5.20
Multifunctional matrices for oral peptide delivery.
A. Bernkop-Schnürch (2001)
10.1002/DMRR.207
Development of oral insulin: progress and current status.
J. Still (2002)
10.1016/0168-3659(93)90071-C
Vancomycin and insulin used as models for oral delivery of peptides
R. S. Geary (1993)
10.1023/A:1011940718534
Pulsatile Drug Release from an Insoluble Capsule Body Controlled by an Erodible Plug
I. Krögel (2004)
10.1080/10611860902839502
Colonic treatments and targets: issues and opportunities
E. McConnell (2009)
10.1016/S0168-3659(96)01582-9
The rationale for peptide drug delivery to the colon and the potential of polymeric carriers as effective tools
A. Rubinstein (1997)
10.1016/0168-3659(90)90011-H
Protease inhibitors and penetration enhancers as approaches to modify peptide absorption
V. Lee (1990)
10.1016/S0168-3659(01)00541-7
Modulation of active pharmaceutical material release from a novel 'tablet in capsule system' containing an effervescent blend.
M. Gohel (2002)
10.1016/S0928-0987(02)00221-X
Microbially triggered drug delivery to the colon.
V. Sinha (2003)
10.1615/CRITREVTHERDRUGCARRIERSYST.V20.I23.30
Emerging trends in oral delivery of peptide and protein drugs.
R. Mahato (2003)
10.1177/193229680900300322
Oral Insulin: The Rationale for This Approach and Current Developments
E. Arbit (2009)
10.1517/17425247.5.4.403
Developments in polymeric devices for oral insulin delivery
V. Babu (2008)
10.3109/03639048909052548
A New Ibuprofen Pulsed Release Oral Dosage Form
U. Conte (1989)
10.1016/S0378-5173(02)00429-5
Studies on lactulose formulations for colon-specific drug delivery.
M. Katsuma (2002)
10.1016/0168-3659(85)90030-6
The design and evaluation of controlled release systems for the gastrointestinal tract
S. S. Davis (1985)
10.1111/j.2042-7158.1992.tb05463.x
Improvement of Large Intestinal Absorption of Insulin by Chemical Modification with Palmitic Acid in Rats
M. Hashizume (1992)
10.1248/BPB.19.897
Oral administration of insulin as poly(vinyl alcohol)-gel spheres in diabetic rats.
T. Kimura (1996)
10.1136/gut.31.1.106
Non-invasive method for delivery of tracer substances or small quantities of other materials to the colon.
A. Chacko (1990)
10.1016/0378-5173(94)00117-0
Effects of bile salts on brush-border and cytosolic proteolytic activities of intestinal enterocytes
J. P. Bai (1994)
10.1016/s0021-9258(18)89012-3
Identification of insulin receptors on the mucosal surface of colon epithelial cells.
D. Pillion (1985)
10.1016/J.ADDR.2004.08.005
Regulation of intestinal epithelial function: a link between opportunities for macromolecular drug delivery and inflammatory bowel disease.
D. Siccardi (2005)
10.1517/17425247.3.6.763
Non-invasive routes for insulin administration: current state and perspectives
C. González (2006)
10.1016/J.ADDR.2004.08.011
New oral delivery systems for treatment of inflammatory bowel disease.
D. Friend (2005)
10.1248/BPB.18.1718
Absorption of insulin using water-in-oil-in-water emulsion from an enteral loop in rats.
A. Matsuzawa (1995)
10.1016/J.JCONREL.2003.08.012
A pulsatile drug delivery system based on rupturable coated hard gelatin capsules.
T. Bussemer (2003)
10.2165/00003495-200565140-00006
Advances in Colonic Drug Delivery
A. Basit (2012)
10.1016/0378-5173(93)90418-F
Enteral insulin delivery by microspheres in 3 different formulations using Eudragit L100 and S100
I. Morishita (1993)
10.1023/A:1015835017916
Chemical Stability of Insulin. 1. Hydrolytic Degradation During Storage of Pharmaceutical Preparations
J. Brange (2004)
Enzymatic barriers for GI peptide and protein delivery.
J. Woodley (1994)
10.1002/JPS.20063
Scintigraphic evaluation of a novel colon-targeted delivery system (CODES) in healthy volunteers.
M. Katsuma (2004)
10.1016/S0169-409X(97)00497-3
Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption
J. Hunter (1997)
10.1080/10611860290022688
Absorption Enhancing Effect of Labrasol on the Intestinal Absorption of Insulin in Rats
S. Eaimtrakarn (2002)
10.1016/S0140-6736(01)05842-1
Insulins today and beyond
D. Owens (2001)
10.1016/S0168-3659(01)00232-2
Development and characterization of a novel peroral peptide drug delivery system.
F. Dorkoosh (2001)
10.1136/gut.27.8.886
Transit of pharmaceutical dosage forms through the small intestine.
S. Davis (1986)
10.1002/JPS.21012
Tricalcium phosphate delayed release formulation for oral delivery of insulin: a proof-of-concept study.
W. Paul (2008)
10.1208/s12249-011-9581-6
A Novel Injection-Molded Capsular Device for Oral Pulsatile Delivery Based on Swellable/Erodible Polymers
A. Gazzaniga (2011)
10.1016/S0168-3659(98)00090-X
New preparation method of intestinal pressure-controlled colon delivery capsules by coating machine and evaluation in beagle dogs.
Z. Hu (1998)
10.1016/0168-3659(92)90113-6
The colon as a site for drug delivery
R. Mrsny (1992)
10.1016/0169-409X(92)90015-I
C) Means to enhance penetration
E. S. Swenson (1992)
10.1615/CRITREVTHERDRUGCARRIERSYST.V18.I5.10
Pulsatile drug-delivery systems.
T. Bussemer (2001)
10.1211/0022357991776976
Enhanced Permeability of Insulin across the Rat Intestinal Membrane by Various Absorption Enhancers: Their Intestinal Mucosal Toxicity and Absorption‐enhancing Mechanism of n‐Lauryl‐β‐D‐maltopyranoside
T. Uchiyama (1999)
10.1016/j.ijpharm.2007.12.037
Nanoparticles of quaternized chitosan derivatives as a carrier for colon delivery of insulin: ex vivo and in vivo studies.
A. Bayat (2008)
10.1023/A:1015806211556
Gastrointestinal Transit and Systemic Absorption of Captopril from a Pulsed-Release Formulation
I. Wilding (2004)
10.1016/S0378-5173(00)00411-7
The dose-related hypoglycemic effects of insulin emulsions incorporating highly purified EPA and DHA.
M. Morishita (2000)
10.1007/978-1-4613-1057-0_12
Immunoreactive pancreatic secretory trypsin inhibitor in gastrointestinal mucosa.
M. Bohe (1988)



This paper is referenced by
10.4155/fseb2013.13.79
Oral delivery of macromolecules: highlighting the challenges to maximize opportunities
Aoife M. O'Mahony (2016)
10.1016/j.ejps.2014.12.020
Enteric-coating of pulsatile-release HPC capsules prepared by injection molding.
E. Macchi (2015)
10.1007/s12033-014-9835-0
Production of Recombinant Human Growth Hormone Conjugated with a Transcytotic Peptide in Pichia pastoris for Effective Oral Protein Delivery
J. Lee (2015)
10.13130/MACCHI-ELENA_PHD2014-02-25
CAPSULAR DEVICES FOR ORAL MODIFIED RELEASE OF DRUGS PREPARED BY INJECTION MOLDING
E. Macchi (2014)
10.1021/acs.biomac.6b00512
Self-Assembly of pH-Responsive Microspheres for Intestinal Delivery of Diverse Lipophilic Therapeutics.
X. Zhou (2016)
10.1039/C8TB02113A
Preparation and characterization of layer-by-layer hypoglycemic nanoparticles with pH-sensitivity for oral insulin delivery.
L. Zhang (2018)
10.1517/17425247.2013.743528
Development, evaluation and pharmacokinetics of time-dependent ketorolac tromethamine tablets
Sateesh Kumar Vemula (2013)
10.5530/JYP.2015.4.12
Colon Specific Drug Delivery: Effect of Eudragit Enteric Coating on Hydroxypropyl Methylcellulose Matrix Tablets of Flurbiprofen
Sateesh Kumar Vemula (2015)
10.1039/c8bm01485j
Enhanced oral absorption of insulin using colon-specific nanoparticles co-modified with amphiphilic chitosan derivatives and cell-penetrating peptides.
F. Guo (2019)
Obtenção e caracterização de filmes de misturas de amido resistence e pectina como estratégia para liberação cólon específica de fármacos
A. B. Meneguin (2012)
Novos Sistemas Farmacêuticos para Administração Oral
Joana Raquel Tavares Lopes (2012)
10.1016/j.ijpharm.2013.05.043
Film coatings for oral colon delivery.
A. Maroni (2013)
Design, development and in vitro evaluation of colon specific, pulsatile drug delivery system of lornoxicam
Balkrishna Gaikwad (2020)
10.15171/PS.2019.14
Non-Invasive and Less Degradative Ways of Insulin Administration
S. Allahyari (2019)
10.1016/j.ejps.2020.105509
Salcaprozate sodium (SNAC) enhances permeability of octreotide across isolated rat and human intestinal epithelial mucosae in Ussing chambers.
Sarinj Fattah (2020)
10.1016/J.JDDST.2017.06.003
Evaluation of retrograded starch as excipient for controlled release matrix tablets
Ana Cristina Diniz Recife (2017)
10.1080/10837450.2019.1691591
Calcium-oligochitosan-pectin microcarrier for colonic drug delivery
S. Stealey (2019)
10.4103/2230-973X.176456
Insulin delivery methods: Past, present and future
R. Shah (2016)
10.1088/0957-4484/23/9/095101
Solid lipid nanoparticles with and without hydroxypropyl-β-cyclodextrin: a comparative study of nanoparticles designed for colonic drug delivery.
G. Spada (2012)
FORMULATION AND EVALUATION OF NAPROXEN CHRONOMODULATED PULSATILE DRUG DELIVERY SYSTEM
M. N. K. Reddy (2015)
10.1007/s13318-014-0210-0
Pharmacokinetics of colon-specific pH and time-dependent flurbiprofen tablets
Sateesh Kumar Vemula (2014)
10.1016/j.carbpol.2019.115506
Insulin-loaded mucoadhesive nanoparticles based on mucin-chitosan complexes for oral delivery and diabetes treatment.
Momoh A. Mumuni (2020)
10.4155/tde-2016-0081
Diabetes management strategies: can nanoparticles be used to therapeutically deliver insulin?
S. Mazzucchelli (2017)
10.1016/j.ejpb.2016.05.009
Estimation of design space for an extrusion-spheronization process using response surface methodology and artificial neural network modelling.
T. Sovány (2016)
10.1016/j.ejmech.2012.12.011
Predictive modeling of insulin release profile from cross-linked chitosan microspheres.
S. Jose (2013)
10.1021/jf500472b
Resistant starch film-coated microparticles for an oral colon-specific polypeptide delivery system and its release behaviors.
Wenbei Situ (2014)
10.1016/j.ijpharm.2016.05.036
Hot-melt extruded filaments based on pharmaceutical grade polymers for 3D printing by fused deposition modeling.
A. Melocchi (2016)
10.1016/j.nano.2020.102277
Adapted Nano-carriers for Gastrointestinal Defence Components: Surface Strategies and Challenges.
Wenjun Wang (2020)
La libération modifiée de principes actifs, développement de deux approches
Bérangère Dekyndt (2015)
10.5772/58538
Nanoparticle Insulin Drug Delivery — Applications and New Aspects
H. Elçioğlu (2014)
10.1016/j.carbpol.2018.03.025
Starch film-coated microparticles for oral colon-specific drug delivery.
J. Chen (2018)
10.3390/pharmaceutics11110565
Evaluation of Sucrose Laurate as an Intestinal Permeation Enhancer for Macromolecules: Ex Vivo and In Vivo Studies
Fiona McCartney (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar